An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

Iman Jilani, Hagop Kantarjian, Homan Faraji, Mercedes Gorre, Jorge Cortes, Oliver Ottmann, Kapil Bhalla, Susan O'Brien, Francis Giles, Maher Albitar

Research output: Contribution to journalArticle

Abstract

We have developed a simplified sandwich immunoassay to measure free circulating total and phosphorylated fusion BCR-ABL protein in patients with the t(9;22)(q34;q11) chromosomal translocation. The assay is based on immunoprecipitating BCR-ABL protein using beads coated with anti-BCR antibody and detecting the fusion protein with anti-ABL antibody and flow cytometry. We show that this method allows the quantification of this protein in the plasma and may allow the measurement of tumor load. This method also allows the measurement of the level of phosphorylation of the immunoprecipitated BCR-ABL using antibodies against phosphorylated ABL protein, which can be used for monitoring of therapy with kinase inhibitors. The sensitivity of this immunoassay was comparable to the sensitivity of reverse transcription-polymerase chain reaction (RT-PCR) assay. This technique is useful in monitoring patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), but the same approach can be used in other translocations and has the potential of multiplexing.

Original languageEnglish (US)
Pages (from-to)936-943
Number of pages8
JournalLeukemia Research
Volume32
Issue number6
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

Immunoassay
Anti-Idiotypic Antibodies
Proteins
Genetic Translocation
Physiologic Monitoring
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tumor Burden
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reverse Transcription
Blood Proteins
Flow Cytometry
Phosphotransferases
Phosphorylation
Polymerase Chain Reaction
Antibodies
Therapeutics

Keywords

  • BCR-ABL
  • Beads
  • CML
  • Fusion protein
  • Imatinib
  • MDR
  • Phosphorylation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. / Jilani, Iman; Kantarjian, Hagop; Faraji, Homan; Gorre, Mercedes; Cortes, Jorge; Ottmann, Oliver; Bhalla, Kapil; O'Brien, Susan; Giles, Francis; Albitar, Maher.

In: Leukemia Research, Vol. 32, No. 6, 01.06.2008, p. 936-943.

Research output: Contribution to journalArticle

Jilani, I, Kantarjian, H, Faraji, H, Gorre, M, Cortes, J, Ottmann, O, Bhalla, K, O'Brien, S, Giles, F & Albitar, M 2008, 'An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation', Leukemia Research, vol. 32, no. 6, pp. 936-943. https://doi.org/10.1016/j.leukres.2007.11.023
Jilani, Iman ; Kantarjian, Hagop ; Faraji, Homan ; Gorre, Mercedes ; Cortes, Jorge ; Ottmann, Oliver ; Bhalla, Kapil ; O'Brien, Susan ; Giles, Francis ; Albitar, Maher. / An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. In: Leukemia Research. 2008 ; Vol. 32, No. 6. pp. 936-943.
@article{3f6974046dbd4263b3ed2feeb4ab385f,
title = "An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation",
abstract = "We have developed a simplified sandwich immunoassay to measure free circulating total and phosphorylated fusion BCR-ABL protein in patients with the t(9;22)(q34;q11) chromosomal translocation. The assay is based on immunoprecipitating BCR-ABL protein using beads coated with anti-BCR antibody and detecting the fusion protein with anti-ABL antibody and flow cytometry. We show that this method allows the quantification of this protein in the plasma and may allow the measurement of tumor load. This method also allows the measurement of the level of phosphorylation of the immunoprecipitated BCR-ABL using antibodies against phosphorylated ABL protein, which can be used for monitoring of therapy with kinase inhibitors. The sensitivity of this immunoassay was comparable to the sensitivity of reverse transcription-polymerase chain reaction (RT-PCR) assay. This technique is useful in monitoring patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), but the same approach can be used in other translocations and has the potential of multiplexing.",
keywords = "BCR-ABL, Beads, CML, Fusion protein, Imatinib, MDR, Phosphorylation",
author = "Iman Jilani and Hagop Kantarjian and Homan Faraji and Mercedes Gorre and Jorge Cortes and Oliver Ottmann and Kapil Bhalla and Susan O'Brien and Francis Giles and Maher Albitar",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.leukres.2007.11.023",
language = "English (US)",
volume = "32",
pages = "936--943",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

AU - Jilani, Iman

AU - Kantarjian, Hagop

AU - Faraji, Homan

AU - Gorre, Mercedes

AU - Cortes, Jorge

AU - Ottmann, Oliver

AU - Bhalla, Kapil

AU - O'Brien, Susan

AU - Giles, Francis

AU - Albitar, Maher

PY - 2008/6/1

Y1 - 2008/6/1

N2 - We have developed a simplified sandwich immunoassay to measure free circulating total and phosphorylated fusion BCR-ABL protein in patients with the t(9;22)(q34;q11) chromosomal translocation. The assay is based on immunoprecipitating BCR-ABL protein using beads coated with anti-BCR antibody and detecting the fusion protein with anti-ABL antibody and flow cytometry. We show that this method allows the quantification of this protein in the plasma and may allow the measurement of tumor load. This method also allows the measurement of the level of phosphorylation of the immunoprecipitated BCR-ABL using antibodies against phosphorylated ABL protein, which can be used for monitoring of therapy with kinase inhibitors. The sensitivity of this immunoassay was comparable to the sensitivity of reverse transcription-polymerase chain reaction (RT-PCR) assay. This technique is useful in monitoring patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), but the same approach can be used in other translocations and has the potential of multiplexing.

AB - We have developed a simplified sandwich immunoassay to measure free circulating total and phosphorylated fusion BCR-ABL protein in patients with the t(9;22)(q34;q11) chromosomal translocation. The assay is based on immunoprecipitating BCR-ABL protein using beads coated with anti-BCR antibody and detecting the fusion protein with anti-ABL antibody and flow cytometry. We show that this method allows the quantification of this protein in the plasma and may allow the measurement of tumor load. This method also allows the measurement of the level of phosphorylation of the immunoprecipitated BCR-ABL using antibodies against phosphorylated ABL protein, which can be used for monitoring of therapy with kinase inhibitors. The sensitivity of this immunoassay was comparable to the sensitivity of reverse transcription-polymerase chain reaction (RT-PCR) assay. This technique is useful in monitoring patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), but the same approach can be used in other translocations and has the potential of multiplexing.

KW - BCR-ABL

KW - Beads

KW - CML

KW - Fusion protein

KW - Imatinib

KW - MDR

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=40849147403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849147403&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.11.023

DO - 10.1016/j.leukres.2007.11.023

M3 - Article

C2 - 18155764

AN - SCOPUS:40849147403

VL - 32

SP - 936

EP - 943

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -